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Background: Spondyloarthritis (SpA) and hidradenitis suppurativa (HS) share several 
pathophysiological features. 
 
Objective: To investigate the prevalence of self-reported clinical SpA features in HS 
patients and to identify patient characteristics associated with these features.  
 
Methods: Cross-sectional study. A questionnaire concerning the presence of ASAS axial 
and peripheral SpA entry classification criteria and other SpA features was sent to all HS 
patients in two Dutch tertiary HS referral centers.  
 
Results: Overall, 47.2% (620/1313) of questionnaires were eligible for analysis. Of these, 416 
(67.1%) patients fulfilled ≥1 of the four ASAS entry criteria. Entry criteria for axial and 
peripheral SpA were reported by 72.8% and 27.2%, respectively. The large majority (87%) 
reported ≥1 additional clinical SpA features: one feature by 32.9%, two by 29.1%, three by 
16.1%, and ≥4 by 8.9%. In comparison to patients without self-reported entry criteria 
(n=204), patients with self-reported fulfillment were significantly more frequently female, 
had higher BMI, were more often ex- or current smokers, had longer HS disease duration, 
and more active HS symptoms at the survey response time. 
 
Limitations: Non-responder bias and self-reporting design.  
 
Conclusion: Self-reported clinical SpA features are common in HS patients, especially in 







Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating inflammatory skin 
disease of the inverse body regions.1 Hidradenitis suppurativa is associated with a range of 
somatic and psychological comorbidities including inflammatory bowel disease (IBD), 
particularly Crohn’s disease, metabolic syndrome, depression, and probably rheumatologic 
conditions such as spondyloarthritis (SpA).1,2  
Spondyloarthritis, previously termed seronegative spondyloarthritides, is a heterogeneous 
group of interrelated chronic inflammatory articular rheumatic conditions, which include 
ankylosing spondylitis (AS), psoriatic arthritis, arthritis related to IBD, reactive arthritis, 
and undifferentiated SpA.3 These conditions share clinical symptoms and are associated 
with the HLA-B27 gene. In most patients, the first symptoms develop in the third or fourth 
decade of life, and males are more frequently affected.3 The diagnosis of SpA is made by a 
rheumatologist and is mainly based on the presence of “SpA features”, which includes 
spinal (axial) features such as sacroiliitis and spondylitis; peripheral features such as 
peripheral arthritis, enthesitis, and dactylitis; and the so called extra-articular 
manifestations uveitis, psoriasis, and IBD.3 Spondyloarthritis features may develop during 
the course of the disease and may come and go and often do not occur simultaneously. 
The probability of SpA increases when more of these features have occurred in a patient.4,5  
Spondyloarthritis can be categorized as predominantly axial or peripheral depending on 
the main involved articular features.3 The latest and currently most used classification 
criteria were developed by the Assessment in SpondyloArthrtis international Society 
(ASAS) (Figure 1).6-8 These classification criteria comprise clinical features of SpA, 
laboratory (e.g. HLA-B27 positivity) and imaging features (e.g. sacroiilitis on radiography 
and/or magnetic resonance imagining (MRI)).6-9 According to ASAS, four “entry criteria” 
for the classification of SpA into (predominantly) axial or peripheral SpA exist. The entry 
criteria for axial SpA begins with “back pain ≥3 months with age of onset before 45 years 
(with or without the presence of peripheral manifestations)”.7 The three entry criteria for 
peripheral SpA are “peripheral arthritis, enthesitis or dactylitis, without axial involvement” 
(Figure 1).8  
Until recently, the association between SpA and HS had only been described in limited 
publications, mostly concerning case reports and small retrospective case series.10-16 Two 
recent studies on the prevalence of SpA in HS patients showed large differences in results. 
The first study suggested a prevalence of SpA of 2.3 to 3.7%, depending on the clinical and 

















Back pain ≥3 months, onset <45 years old  
(with or without peripheral manifestations) 
 
 Entry criteria: 
In patients with peripheral manifestations ONLY: 








≥1 other SpA features 
or Clinical group 
HLA-B27-positive plus 








Additional SpA features 
 
 




≥2 other additional 
SpA features 
 ▪ IBP  
▪ Arthritis 
▪ Heel enthesitis 
▪ Uveitis  
▪ Dactylitis  
▪ Psoriasis 
▪ IBD 
▪ Good response of back pain  
  to NSAIDs   
▪ Family history of SpA  
▪ HLA-B27 positive 
▪ Increased CRP
†
   
  
▪ Uveitis 
▪ Psoriasis  
▪ IBD  
▪ Preceding gastro-  
  intestinal or  
  genitourinary  
  infection  




▪ IBP (ever)  
▪ Arthritis  
▪ Enthesitis (any) 
▪ Dactylitis 
▪ Family history of     
  SpA 
 
   
 
Sensitivity and specificity of ASAS classification criteria 
Axial SpA criteria: sensitivity 82.9%; specificity 84.4%; n=649.
7 
Peripheral SpA criteria: sensitivity 77.8%; specificity 82.2%; n=266.
8 




Figure 1. Classification criteria of axial and peripheral spondyloarthritis according to the 
Assessment in SpondyloArthritis international Society (ASAS)  
 
ASAS, Assessment of SpondyloArthritis international Society; SpA, spondyloarthritis; IBP, inflammatory back 
pain; CRP, C-reactive protein; IBD, inflammatory bowel disease (Crohn’s disease / colitis ulcerosa). 
 
* Either active inflammation detected by MRI highly suggestive of sacroiliitis associated with SpA, or definite 
radiographic sacroiliitis according to the modified New York criteria.  
† Increased CRP is considered a SpA feature in the context of chronic back pain. 
 













HS patients.17,18 Both prevalence rates are higher than the prevalence of SpA in the general 
population, which is approximately 1%.3,4  
Because of these discrepancies in prevalence rates and to obtain insight in which HS 
patients report SpA features and possibly have a higher chance of SpA, we undertook this 
cross-sectional study in two large HS cohorts in the Netherlands. Our objective was to 
investigate the prevalence of self-reported clinical SpA features in HS patients and to 




Subjects and design 
In this multicenter cross-sectional study, adult patients with a billing code for HS 
(between 2010 and 2016) in the dermatology departments of the University Medical Center 
Groningen (UMCG) and Erasmus Medical Center (EMC) received a postal questionnaire 
and were requested to return the completed questionnaire by post using a pre-stamped 
return envelope. A reminder was sent to the non-respondents after four weeks. Unopened 
returned questionnaires and insufficiently answered surveys (no information on SpA entry 
criteria) were excluded. According to Dutch law, no formal informed consent was needed 
for this type of study as verified by the UMCG ethical committee.  
 
Questionnaire about clinical SpA features 
The questionnaire comprised questions about clinical SpA features that are easily self-
identifiable by patients. These questions were formulated based on the ASAS definitions 
for axial and peripheral SpA entry criteria and additional clinical SpA features in the past 
or present.6-9 The questions included: a history of back pain existing ≥3 months with an 
age of onset <45 years; inflammatory back pain (IBP); response of back pain to non-steroid 
anti-inflammatory drugs (NSAIDs); peripheral arthritis (swollen joints); enthesitis of the 
Achilles tendon; dactylitis; ophthalmologist diagnosed uveitis; physician diagnosed 
psoriasis including pustulosis palmoplantaris; gastroenterologist diagnosed IBD (Crohn’s 
disease or ulcerative colitis); and a positive family history of SpA and SpA related 
conditions (psoriasis, uveitis, and IBD) in first or second degree relatives. When 
applicable, the SpA questions were illustrated with colored prototypical pictures. In 
addition, data on age, gender, length, weight, smoking habits, and HS characteristics such 
as age of symptom onset and current HS symptoms to derive the Hurley and refined 






Descriptive statistics are reported as mean ± standard deviation (SD) or median 
(interquartile range (IQR)) for normally distributed and non-normally distributed data, 
respectively. Determined was how many HS patients reported the ASAS “entry criteria” for 
classification of SpA. Subsequently, the prevalence of “additional” self-reported SpA 
features to the entry criteria were calculated. Comparison between HS patients with and 
without self-reported SpA entry criteria was done using the independent-sample t or 
Mann-Whitney U tests for continuous and chi square or Fisher’s exact tests for 
dichotomous variables. It was reported when ≥5% of data was missing per variable. P-
values ≤ 0.05 were considered as statistically significant. Statistics were performed using 




Inclusion and exclusion 
In total, 1313 HS patients received a questionnaire of which 730 (55.6%) were returned 
(Figure 2). Of these 730 questionnaires, 110 (15.1%) were excluded due to unopened returns 
(n=70), insufficiently answered surveys (n=32) and other reasons (n=8). Subsequently, 620 
(47.2%) questionnaires were eligible for analysis (Figure 2).  
The excluded patients (n=693) were more frequently male (36.7 vs. 29.8%, p=0.010) and 
were younger (40.8 ± 17.5 vs. 43.4 ± 13.9, p<0.001) compared with the included patients. 
 
Subjects 
Overall, 70.2% (434/620) of respondents were female, with a mean age of 43.4 ± 13.9 years, 
and mean BMI of 28.0 ± 5.8 kg/m2. Furthermore, 83.5% (518/620) patients were ex- or 
current smokers (Table 1). One fourth (24.8%) of patients had no HS symptoms at the time 
of the survey, 20.6% were categorized into Hurley stage I, 46.1% into stage II and 8.5% into 
stage III. An overview of the distribution within the refined Hurley classification is shown 
in Table 1. The patient characteristics were similar between UMCG and EMC cohorts (data 
not shown). 
 
Prevalence of clinical SpA features 
In total, 416 (67.1%) HS patients fulfilled ≥1 of the four axial or peripheral ASAS entry 
criteria (Figure 3). Moreover, 87% of these patients reported ≥1 additional clinical SpA 
features: one additional feature was reported by 137 (32.9%) patients, two features by 
121 (29.1%), three features by 67 (16.1%), and ≥4 features by 37 (8.9%) patients. Table 2 





























Figure 2. Flow chart of exclusion of questionnaires 
 
HS, hidradenitis suppurativa; UMCG, University Medical Center Groningen; EMC, Erasmus Medical Center. 
 
 
Of the 416 patients who fulfilled ≥1 of the four ASAS entry criteria, 72.8% (303/416) 
reported to fulfill the ASAS entry criteria for axial SpA and IBP was reported by 27.7%. 
Of the 303 patients, 82.2% reported ≥1 additional clinical SpA feature. The other 27.2% 
(113/416) reported to fulfill the ASAS entry criteria for peripheral SpA. Of these 
patients, 85.0% reported an episode of peripheral arthritis, 22.1% enthesitis of the 
Achilles tendon and 22.1% dactylitis. One peripheral SpA feature was reported by 
72.6% (n=82), two by 25.7% (n=29), and 1.8% (n=2) reported all three peripheral SpA 
features. All these 113 patients also reported ≥1additional clinical SpA features as well 
(Figure 3).  
The remaining 32.9% (204/620) patients did not fulfill any of the ASAS entry criteria. 
Of these patients, 71.6% did not report the presence of additional SpA features, 23.0% 
reported one feature, and 5.4% two features (Figure 3). Family history of SpA 
conditions was reported most frequently (21.1%), followed by IBD (6.9%), psoriasis 
(6.4%), and uveitis (1.0%). 
  
1313 
(UMCG: 654; EMC: 659) 
 
Questionnaires sent to all HS 
patients with billing code HS at the 
UMCG and EMC between  
2010-2016 
730 (55.6%) 









70 unopened returns to sender;  
32 insufficiently answered questions; 
5 unwilling to participate; 
2 recently deceased;  
1 temporarily lives abroad. 
620 (47.2%) 
(UMCG: 350; EMC: 270) 
 




Table 1. Patient characteristics included hidradenitis suppurativa patients (n=620) 
 
 
Data are presented as number of patients (%) or mean ± standard deviation. 
 
Missing data ≥5%: BMI (6.8%), age of onset HS (6.6%), disease duration of HS (6.5%), Hurley classification stage 
(5.2%), refined Hurley classification stage (6.0%).  
 




Patient characteristics associated with SpA features in HS 
In comparison to patients without self-reported entry criteria (204/620), patients 
fulfilling the ASAS entry criteria (416/620) were more frequently female (74.8% vs. 
60.9%, p<0.001), had a higher BMI (28.6 ± 5.9 vs. 26.7 ± 5.3, p<0.001), were more often 
ex- or current smokers (87.9% vs. 76.2%, p=0.001), had a longer HS disease duration 
(19.9 ± 12.8 vs. 17.0 ± 12.4, p=0.012), and reported more active HS at time of the survey 
response reflected by the Hurley and refined Hurley classification distribution (both 
p<0.001) (Table 3).  
  
Patient characteristics  
Age, years 43.4 ± 13.9 
Female gender 434 (70.2) 
Age of onset HS, years 24.0 ± 12.5 
Disease duration of HS, years 18.9 ± 12.7 
BMI, kg/m
2 
28.0 ± 5.8 
Smoking status  
   Non-smoker 
   Ex-smoker 




Hurley classification stage  
   Not active 
   Hurley I 
   Hurley II 





Refined Hurley classification stage  
   Not active 
   Refined Hurley IA 
   Refined Hurley IB 
   Refined Hurley IC 
   Refined Hurley IIA 
   Refined Hurley IIB 
   Refined Hurley IIC 




























































Figure 3. Flowchart of self-reported ASAS classification entry criteria for spondyloarthirits in 
patients with hidradenitis suppurativa 
 




Included HS patients 
416 (67.1%) 
With fulfillment of ≥1 out of 4  
ASAS entry criteria for SpA 
204 (32.9%) 
Without fulfillment of any 
ASAS entry criteria for SpA 
303 (72.8%) 
Axial SpA entry criterion 
Back pain ≥3 months, onset  
<45 years old (without or with 
peripheral manifestations) 
113 (27.2%) 
Peripheral SpA entry criteria 
Peripheral arthritis (swollen joint) 
and/or enthesitis of Achilles 
tendon and/or dactylitis 
249 (82.2%) 
≥1 additional self-reported 
clinical SpA features  
113 (100%) 
≥1 additional self-reported 
clinical SpA features  
58 (28.4%) 
≥1 self-reported  
clinical SpA features  
249 (82.2%) 
≥1 additional self-reported 
clinical SpA features  
113 (100%) 
≥1 additional self-reported 
clinical SpA features  
62 
 
Table 2. Overview of the prevalence of self-reported spondyloarthritis entry criteria and 
features in patients with hidradenitis suppurativa 
 




Total number of self-reported SpA features  
in addition to the entry criteria* 
 
    0 features  54 (13.0) 
    1 feature  137 (32.9) 
    2 features  121 (29.1) 
    3 features  67 (16.1) 
    ≥4 features  37 (8.9) 
  
SpA-features (self-reported)  
    Inflammatory back pain
‡
  84 (20.2) 
    Effect of NSAIDs on back pain  
        Good response (>50% response) 63 (22.0) 
        No or under 50% response 93 (32.5) 
        No NSAIDs used 30 (45.5) 
    Peripheral arthritis (swollen joints) 248 (59.6) 
    Enthesitis (Achilles tendon) 66 (15.9) 
    Dactylitis  83 (20.0) 
    Uveitis
§
 13 (3.2) 
    Psoriasis (incl. pustulosis palmoplantaris)
§
 39 (9.4) 
    Inflammatory bowel disease
§
 31 (7.6) 
        Crohn’s disease 19 (4.7) 
        Ulcerative colitis 12 (2.9) 








SpA, spondyloarthritis; ASAS, Assessment of SpondyloArthritis international Society; NSAIDs, nonsteroidal anti-
inflammatory drugs. 
 
* Additional self-reported SpA-features: inflammatory back pain, inflammatory bowel syndrome, uveitis, 
psoriasis, good effect of non-steroidal drugs on back pain, family history of spondyloarthritis, dactylitis, 
enthesitis of the Achilles tendon, and peripheral arthritis (swollen joint). 
† ASAS entry criteria for axial and peripheral SpA: “back pain for ≥3 months with age of onset <45 years” and 
“peripheral arthritis, enthesitis or dactylitis”, respectively. 
‡ Inflammatory back pain: at least four out of five ASAS criteria for inflammatory back pain need to be fulfilled: 
insidious onset, pain at night (with improvement upon getting up), age at onset <40 years, improvement with 
exercise, and no improvement with rest.
10
  
§ Physician diagnosed. 
# Family history for SpA in 1st/2nd degree relatives: ankylosing spondylitis, psoriatic arthritis, psoriasis, uveitis, 






Table 3. Patient characteristics between hidradenitis suppurativa patients with versus without 
fulfillment of spondyloarthritis entry criteria 
 
 
HS, hidradenitis suppurativa; BMI, Body Mass Index. 
 




This study shows that self-reported clinical SpA features are common in HS patients: 67% 
reported ≥1 ASAS entry criteria and the large majority of these patients (87%) reported 
additional clinical SpA features. Approximately 75% of these patients reported long-term 
back pain as entry criteria for axial SpA of which approximately 28% reported 
inflammatory back pain. 
In this study, we used the ASAS criteria for axial and peripheral SpA, with a previously 
reported sensitivity and specificity of 79.5% and 83.3% respectively according to the 
diagnosis made by the rheumatologist.7,8 Important to mention is that the ASAS criteria 
were developed as classification criteria for clinical research and not as diagnostic criteria.8 
However, for the diagnosis of SpA, the presence and number of clinical SpA features seem 
important since the probability of a SpA diagnosis increases if more of these SpA features 
are present.4,5,19-21 The relevance of these clinical SpA features for the diagnosis can be 
 Fulfillment of ≥1 of 4 
ASAS entry criteria 
No fulfillment of  
ASAS entry criteria 
p-value 
 (n=416) (n=204)  
Age, years 43.8 ± 13.2 42.5 ± 15.2 0.29 
Female gender 311 (74.8) 123 (60.9) <0.001 
Age of onset HS, years 23.4 ± 12.2 25.0 ± 13.1 0.15 
Disease duration of HS, years 19.9 ± 12.8 17.0 ± 12.4 0.012 
BMI, kg/m
2 
28.6 ± 5.9 26.7 ± 5.3 <0.001 
Smoking status   0.001 
   Non-smoker 
   Ex-smoker 
   Current smoker 
50 (12.1) 48(23.8)  
138(33.3) 61(30.2)  
226(54.6) 93(46.0)  
Hurley classification stage   <0.001 
   Not active 
   Hurley I 
   Hurley II 
   Hurley III 
78 (20.1) 68 (34)  
72 (18.6) 47 (12.1)  
198 (51.0) 73 (36.5)  
38 (9.8) 12 (6.1)  
Refined Hurley classification stage   <0.001 
   Not active 
   Refined Hurley IA 
   Refined Hurley IB 
   Refined Hurley IC 
   Refined Hurley IIA 
   Refined Hurley IIB 
   Refined Hurley IIC 
   Refined Hurley III 
78 (20.2) 68 (34.5)  
18 (4.7) 15 (7.6)  
7 (1.8) 7 (3.6)  
49 (12.7) 25 (12.7)  
29 (7.5) 16(8.1)  
45 (11.7) 23 (11.7)  
122 (31.6) 31 (15.7)  
38 (9.8) 12 (6.1)  
64 
 
expressed in likelihood ratios (LR), i.e. ranging from 2.5 for psoriasis to 7.3 for uveitis.21 In 
our study, of the HS patients who reported ≥1 of the ASAS entry criteria for SpA, almost all 
(87%) reported the presence of ≥1 other additional (clinical) SpA features. More than half 
of the patients reported multiple additional SpA features of which 29% reported two 
features, 16% three features, and nearly 9% reported ≥4 features, this further increases the 
diagnostic probability (by calculating the LR product).  
Since over 50% of the HS patients who returned their questionnaire reported multiple SpA 
features, we argue that HS and SpA seem associated which is in line with previous studies. 
In 2014, a prospective study investigated the history of clinical SpA features (arthritis, 
enthesitis, and IBP) in 640 HS patients in France.17 All HS patients with articular 
complaints (n=184) (not further defined), were referred to a rheumatologist and an episode 
of arthritis, enthesitis and/or IPB (determined with the Calin or Berlin criteria) was 
reported in 43 (6.7%) of these patients. Additional diagnostics (HLA-B27, radiography, 
MRI) were done, although not in all patients. Finally, 15 patients fulfilled the ASAS criteria 
for SpA, leading to a prevalence of SpA of 2.3% in 640 HS patients.17 Another French study, 
published in 2017, compared the prevalence of SpA between 39 HS patients and an age and 
gender matched control group without dermatological diseases.18 They reported a 
prevalence as high as 28.2% in the HS group, versus 2.6% in the control group. In this 
study, the rheumatologist used the ASAS classification criteria to diagnose SpA. In both 
studies axial involvement was most common.17,18 The results of both studies are higher 
than the average reported prevalence of SpA of around 1-1.5% in the general population, 
but differ considerably.3,4,17,18 However, both studies reported limitations, such as selection 
bias probablity and incompleteness of additional diagnostic test.17,18 
An association between HS and SpA could be explained by a similar pathogenic 
mechanism, even though the exact pathogenesis of both HS and SpA remains to be 
elucidated. A perturbed immune response is assumed to be involved in both conditions, 
sharing dysregulation of tumor necrosis factor-alpha (TNF-α), interleukin-1, interleukin-12, 
interleukin-23 and interleukin-17 pathways.3,22-24 Moreover, both conditions are also 
associated with IBD.25-27 Both HS and SpA show common dysregulated inflammatory 
pathways with IBD, but seem unrelated at first sight due to the different affected end-
organs.3,28 The relationship between all these conditions might be explained by the 
immune‐mediated inflammatory disease (IMID) concept, a theory that is used to 
collectively describe a group of seemingly unrelated conditions that in fact share common 
inflammatory pathways.29 The first hints for common pathogenic pathways within IMID 
conditions were based on the therapeutic effect of TNF-α inhibitors, indicating that an 
imbalance in TNF-α plays an important role in the pathogenesis of all of these IMID 
conditions.29 The IMID concept is already described for IBD and SpA, and based on 





The risk factors smoking and a high BMI are epidemiologically linked to both HS and SpA; 
high prevalence rates are found in both diseases and are associated with a higher disease 
activity.30-34 Interestingly, our results show a significantly higher prevalence of ex- or 
current smokers and a higher mean BMI in the group positive for at least one SpA entry 
criterion, compared to the patients without self-reported SpA entry criteria. Several 
theories are formed about the influence of these risk factors on HS and SpA disease. One 
plausible hypothesis is, that smoking and a higher BMI might alter immunological 
(inflammatory) responses, contributing to HS and SpA disease activity.29,35  
Another notable, significantly more prevalent characteristic in HS patients positive for ≥1 
SpA entry criteria were active HS symptoms at time of the questionnaire response. In line 
with the above, this might suggest that HS disease activity might influence the 
immunological inflammatory responses, possibly increasing chances for other 
inflammatory disease such as SpA. However, one might also suggest that patients with 
active symptoms of one disease, are more likely to respond to a survey as this one.  
Our study has limitations. There is the risk of non-responder bias. Furthermore, this study 
focused on clinical SpA features assumed to be easily self-identified by patients, therefore, 
the developed questionnaire does not cover all clinical SpA features (e.g. the question 
regarding enthesitis was restricted to enthesitis of the Achilles tendon and not enthesitis 
of other sites). A notable finding was that a large number (approximately 50%) HS patients 
reported a positive history of swollen joints (to identify a history of peripheral arthritis). 
This number must be taken with caution since a possible discrepancy between physicians’ 
and patients’ swollen joint count has been shown previously in a systematic review for 
rheumatoid arthritis.36 In order to limit the false positive answers, we added prototypical 
pictures of patients with swollen joints in the self-administered questionnaire. Altogether, 
both underestimation and overestimation of clinical SpA features is possible. We asked 
patients for present and past SpA features and no additional knowledge was available of 
laboratory tests such as the presence of HLA-B27 and imaging to detect sacroiliitis. A 
conformation of a possible SpA diagnosis by a rheumatologist was not part of this study.  
In conclusion, this study demonstrated high prevalence of self-reported ASAS 
classification entry criteria for either axial or peripheral SpA, and additional SpA features 
in HS patients. This strongly suggests a relevant association with SpA. Early recognition of 
possible SpA in HS patients is important for management and outcome in both SpA and 
HS. In this study, the prevalence of SpA features was associated with ‘classic’ HS patient 
(female, overweight, smoker), with longer HS disease duration and symptoms of active HS. 
Further evaluation of these patients, by referral to a rheumatologist, is therefore 
considered. The developed questionnaire in this study might be a useful instrument for the 
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